

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
29 November 2018 (29.11.2018)



(10) International Publication Number
WO 2018/215315 A1

(51) International Patent Classification:

C07D 209/08 (2006.01) **A61P 31/12** (2006.01)
A61K 31/403 (2006.01)

(21) International Application Number:

PCT/EP2018/063028

(22) International Filing Date:

18 May 2018 (18.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17172237.4 22 May 2017 (22.05.2017) EP

(71) Applicants: JANSSEN PHARMACEUTICALS, INC.

[US/US]; 1125 Trenton-Harbourton Road, Titusville,
NJ New Jersey 08560 (US). **KATHOLIEKE**
UNIVERSITEIT LEUVEN [BE/BE]; Waaistraat 6, bus
5105, 3000 Leuven (BE).

(72) Inventors: BONFANTI, Jean-François; c/o Janssen-

Cilag 1 rue Camille Desmoulins, TSA 91003, 92787
Issy-les-Moulineaux Cedex 9 (FR). **KESTELEYN, Bart,**
Rudolf, Romanie; c/o Janssen Pharmaceutica NV Turn-
houtseweg 30, 2340 Beerse (BE). **BARDIOT, Dorothée,**
Alice, Marie-Eve; c/o Cistim Leuven vzw Gaston
Geenslaan 2, 3001 Leuven (Heverlee) (BE). **MARC-**
HAND, Arnaud, Didier, M; c/o Cistim Leuven vzw Gas-
ton Geenslaan 2, 3001 Leuven (Heverlee) (BE). **COESE-**
MANS, Erwin; c/o Janssen Pharmaceutica NV Turnhout-
seweg 30, 2340 Beerse (BE). **FORTIN, Jérôme, Michel,**
Claude; c/o Janssen-Cilag 1 rue Camille Desmoulins, TSA
91003, 92787 Issy-les-Moulineaux Cedex 9 (FR). **MER-**
CEY, Guillaume, Jean, Maurice; c/o Janssen-Cilag 1 rue
Camille Desmoulins, TSA 91003, 92787 Issy-les Moulin-
eaux Cedex 9 (FR). **RABOISSON, Pierre, Jean-Marie,**
Bernard; c/o Janssen Pharmaceutica NV Turnhoutseweg
30, 2340 Beerse (BE).

(74) Agent: GHEDIRA, Rim; Johnson & Johnson Patent Law

Department Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

(57) Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

WO 2018/215315 A1